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Abstract
Purpose: The main purpose of this study was to evaluate the effects of Halofuginone on radiation-induced cardiovascular injury in
a rat model. Methods: Sixty Wistar-Albino rats were divided into six groups (the control group, radiotherapy (RT) only group
Irradiation (IR), 2.5 and 5 μg Halofuginone groups (Hal (2.5)/C and Hal (5.0)/C), and RT plus 2.5 and 5 μg Halofuginone groups
(Hal (2.5)/IR and Hal (5.0)/IR). Rats were exposed to a single dose of 12 Gy irradiation generated by a linear accelerator.
Halofuginone was applied intraperitoneally with daily doses. At the 6th and 16th weeks of RT, 5 rats from each group sacrificed
and; heart and thoracic aorta tissues removed for both light microscopic and electron microscopic examinations. Results: Light
microscopic examinations revealed that the endocardial thickness of all study groups was significantly different at 6th and 16th
week of RT (p < 0.001 for both). Pair-wise comparisons showed that the differences were significant in IR- Hal (2.5)/IR (p <
0.001); IR-Hal (5.0)/IR (p < 0.001); and Hal (2.5)/IR-Hal (5.0)/IR (p = 0.001) at 16th week of RT. There were significant differences
within the study groups regarding to the thoracic aorta fibrosis scores only at 16 th week of RT (p = 0.002). Electron microscopic
examinations demonstrated that there were significant differences between all the groups with respect to heart mitochondria
scores at both 6th week and 16thweeks of RT (p < 0.001 for both). The differences between Hal (2.5)/IR and Hal (5.0)/IR with
respect to the heart mitochondria scores were significant only at 16th week of RT (p = 0.001). Conclusion: These data demon-
strated that Halofuginone may improve radiation-induced cardiovascular injury. The most prominent improvement was ob-
served in higher dose of Halofuginone group after long term follow-up.
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Introduction
Cardiovascular disease and cancer are the two leading causes
of morbidity and mortality worldwide.1 The majority of the
radiation-induced cardiovascular disease has been reported in
patients who previously treated with thoracic irradiation for
Hodgkin’s disease and breast cancer. Estimated relative risk of
fatal cardiovascular events after irradiation for Hodgkin’s
disease and left-sided breast cancer range between 2.2 and 7.2
and 1.0 to 2.2, respectively.2 Risk is life long, and absolute risk
appears to increase with length of time since exposure. Radi-
ation-associated cardiovascular toxicity may in fact be pro-
gressive.3
Primary basic mechanisms behind radiation-induced cardio-
vascular disease appear to be endothelial dysfunction.4-6 The
sequence of endothelial injury, cell detachment, thrombosis
and fibrosis results in significant tissue injury that often limits
radiation oncologist in attempting to deliver curative doses to
a nearby tumor. Fajardo and Steward have demonstrated that
damage to the myocardium develops through three phases of
injury.5 During acute phase a neutrophilic infiltrate develops
involving all layers of the heart and vessels. The latent phase
is notable for remarkably healthy pericardium and myocar-
dium, which shows only slight, progressive fibrosis. Myocar-
dial capillary endothelial cells demonstrate progressive dam-
age leading to obstruction of the lumen and thrombi of fibrin
and platelets. Though healthy endothelial cell replication in
the vicinity occurred, it is generally inadequate and an inev-
itable ischemia leads to progressive fibrosis. Animals begin to
die at approximately 70th day due to extensive fibrosis. The
hallmark of this late stage is extensive fibrosis.2
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Halofuginone is a, low molecular weight plant derived alka-
loid, isolated from the Dichroa febrifuga plant that exhibits
antifibrotic activity and inhibition of type I collagen synthe-
sis.7 As fibrosis is the result of an increase in type I collagen, it
is assumed that selective inhibition of type I collagen syn-
thesis may inhibit formation of fibrosis without affecting
tissue structure.8 To the best of our knowledge there is no
study in the literature observing the effect of Halofuginone
on the radiation-induced cardiovascular injury. The present
study was designed to determine whether Halofuginone




The study included 60 adult female Wistar-Albino rats
(250-300 g), the use of which was approved by the Necmettin
Erbakan University Animal Care and Use Committee. Ani-
mals were housed 4 per cage in a controlled animal holding
room with a 12/12-h light/dark cycle; temperature and rela-
tive humidity were continually monitored to provide stand-
ard laboratory conditions. Food and water were provided ad
libitum. The rats were randomly grouped into four groups
containing 10 rats each: In control group (Control), neither
radiotherapy (RT) nor medication administered.
IR was the RT only group receiving a single dose of RT (12
Gy), but no medication. Hal (2.5)/C and Hal (5.0)/C were 2.5
μg and 5 μg Halofuginone groups and rats in these groups
were applied Halofuginone (Collgard Biopharmaceuticals
Ltd. Petah Tikva, Israel) in a single dose of 2.5 μg and 5 μg
daily intraperitoneal injection for 16 weeks respectively. Hal
(2.5)/IR and Hal (5.0)/IR were defined as 2.5 μg Halofuginone
+ RT and 5 μg Halofuginone + RT groups and rats in these
groups were given Halofuginone in a single dose of 2.5μg and
5 μg daily intraperitoneal injections for 16 weeks, starting
immediately after administration of 12 Gy single dose radio-
therapy.
Irradiation protocol
RT was applied under general anesthesia with intraperitone-
ally administered 90 mg/kg ketamine hydrochloride and 10
mg/kg xyalazine. A single dose of 12 Gy with 6 MV photon
beams was applied via a single anterior field to 2 cm depth
with SAD (source-axis distance) technique. 1 cm elasto-gel
bolus was used to build up the radiation dose on the heart and
to provide contour regularity. The field size was 4 × 4 cm and
included the mediastinum.
Halofuginone protocol
Halofuginone is in crystalline form. Crystalline Halofuginone
was dissolved in a 0.44 M, pH 4.3 lactic acid tampons and
stock solutions of 1-2 mg/ml were prepared and stored at 4°C
at which it could remain stable for at least 4 months. Study
solutions for injection were prepared by diluting the stock
solutions daily using 0.9% NaCl (0.1 mg/1 ml). The study
solutions were used within 1 hour following preparation.
Morphologic studies
At the 6th and 16th weeks of the RT, five animals from each
group were anesthetized and sacrificed by cervical disloca-
tion. The heart and thoracic aorta removed from the chests of
the animals.
Light microscopy
The heart and thoracic aorta samples were excised and fixed
in 10% formaldehyde solution and embedded in paraffin for
light microscopic examination. The slices obtained were
stained with hematoxylen and eosin (H&E) to evaluate the
inflammation, and with immunohistochemical triple staining
to identify the cardiac fibrosis. As a quantitive end point,
extend of the radiation-induced fibrosis, was graded on a scale
of 0 (normal heart-normal aorta) to 3 (severe fibrosis) as de-
scribed in Table 1.
Using the digital images obtained from the selected areas by
light microscopy (Nikon, Labophot-2, Japan) at magnification
x20, the thickness of the endocardium was measured by BAB
system (BAB Bs200Pro Image Analysis Software, BAB
Yazılım Donanım Mühendislik Medikal San.Ve Tic. Ltd. Sti.
Ankara, Turkey). The pathologist was not aware of the
treatment groups at the time of the histological examination
of the specimens. After examining the whole sections for each
rat, the average value was taken as the fibrosis score and mean
values of the groups were calculated.
TABLE 1: The scoring system for fibrosis of the heart and thoracic







The tissue samples which were taken from the animals 6 and
16 weeks after RT were put into 2.5% gluteraldehyde for 24
hours for primary fixation. The same application was done to
the rats of the Halofuginone and control groups after the
administration of the drug or NaCl in the same timing pro-
cedure. Then, these samples were washed with Sorenson’s
Phosphate Buffer solution (pH: 7.4) and they were post-fixed
in 1% osmium tetroxide. After post-fixation, they were
washed with the same buffer and dehydrated in increasing
concentrations of alcohol series. After dehydration, the tis-
sues were washed with propylene oxide and embedded in
epoxy resin embedding media. The semi-thin and ultrathin
sections of the obtained tissue blocks were cut with an ul-
tramicrotome (LKB Nova, Sweden). These semi-thin sections
which were 2 micrometers in thickness were stained with
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methylene blue and examined under a light microscope (Ni-
kon, Japan). Following this procedure, trimming was done to
the tissue blocks and their ultrathin sections which were
about 60 nanometers in thickness were taken by the same
ultramicrotome. These ultra-thin sections were stained with
uranyl acetate and lead citrate and they were examined under
Jeol JEM 1200 EX (Japan) transmission electron microscope.
The electron micrographs of the specimens were taken by the
same microscope.
The parameters which were investigated by electron mi-
croscopy regarding to thoracic aorta samples for each rat were
endothelial cells, subendothelial layer, and internal elastic
membrane, smooth muscle cells of the tunica media, external
elastic membrane and collagen fibers and fibroblasts of tunica
externa (adventitia). Since the only morphological appear-
ance of endothelial cells and the severity of subendothelial
edema were different among groups, a scoring system which
was defined in our previous study was performed based on
these 2 parameters which was listed in Table 2.9
TABLE 2: The scoring system for the damage signs of vascular injury
for electron microscopy.
Score Endothelial Cells Subendothelial Edema
0 Normal No edema
1 Slight thinning Minimal edema
2 Apparent thinning Intensive edema
3 Detachment from base-
ment membrane
4 Detachment from base-
ment membrane and
apparent thinning
In order to define cardiac injury, mitochondrial samples were
examined using a scoring system (Table 3). In each group;
mitochondria were scored in five samples. For every sample;
100 mitochondria were scored; therefore for each group;
totally 500 mitochondria were scored.
TABLE 3: The scoring system for cardiac mitochondria.
Score Mitochondria Score
0 Ultrastructurally normal
1 Mitochondrion with prominent cristae
2 Swollen mitochondrion (cloudy swelling)
3 Amorphous material collection in mitochondrion
Statistical method
The Statistical Package for Social Sciences (SPSS) v. 16.0 was
used for statistical analyses. As the pathological scores were
ordinal in nature, the differences in pathological findings
between the study groups were analyzed using the Krus-
kal-Wallis test. When an overall statistically significant dif-
ference was observed, pair-wise comparisons were performed
using the Mann-Whitney U test. Bonferroni correction was
used for multiple comparisons. A 5% type-I error level was
used for the statistical significance cut-off for overall com-
parisons.
Results
Pathological changes of the heart and the thoracic aorta
samples six weeks after radiotherapy are presented below.
Light microscopy
Thoracic aorta samples
Histopathological examinations of the thoracic aorta samples
revealed a subendothelial edema in the IR group. Moreover
there was a severe inflammation in the tunica adventitia in
this group. However the amount of the subendothelial edema
and inflammation were not severe in Hal (2.5)/IR and Hal
(5.0)/IR groups. There was not any ultrastructural change in
the thoracic aorta samples of the control group, Hal (2.5)/C
and Hal (5.0)/C groups. When the thoracic aorta fibrosis
scores were compared, there were significant difference be-
tween the study groups (p = 0.087). Triple staining revealed
minimal fibrosis in all the RT groups.
Heart samples
There weren’t any ultrastructural changes in the heart sam-
ples of the control group, Hal (2.5)/C and Hal (5.0)/C groups.
Hematoxylen-eosin (H&E) staining did not demonstrate any
pathological findings in IR group except for the minimal
moderate endothelial thickening. Similarly there were
minimal thickening in the endocardium of the Hal (2.5)/IR
and Hal (5.0/IR groups. However the endocardial thickening
of Hal (2.5)/IR and Hal (5.9)/IR groups were not as severe as
IR group. Tripple staining revealed subendocardial fibrosis in
the IR, Hal (2.5)/IR and H al (5.0)/IR groups.
Table 4 shows the endocardial thickness scores of the study
groups. There was significant difference between the study
groups with respect to the endocardial thickness scores at 6th
week of RT (p < 0.001). The endocardial thickness score of the
IR was significantly higher than Hal (2.5)/IR and Hal (5.0)/IR
scores (p values were <0.001 for both). Also there was a sig-
nificant difference between Hal (2.5)/IR and Hal (5.0)/IR in
terms of the endocardial thickness scores (p < 0.001). There
weren’t any significant differences in control and Hal (2.5)/C
(p = 0.393); IR and Hal (5.0)/C (p = 0.739) and; Hal (2.5)/C and
Hal (5.0)/C (p = 0.165).
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TABLE 4: Endocardial thickness values of each study group at 6th weeks and 16th weeks of RT.
Mean Standard Deviation Median Minimum Maximum 7 p
6th week of RT
Endocardial Thick-
ness (micron)
Control 19,48 4,33 18,06 15,01 28,23
<0.001
IR 616,04 70,1 582,6 532,06 718,65
Hal (2.5)/C 21,84 4,98 22,02 16,09 28,03
Hal (5.0)/C 18,34 3,21 18,02 15,06 26,03
Hal (2.5)/IR 466,87 28,55 468,05 412,2 505,13
Hal (5.0)/IR 86,75 24,08 80,67 62,01 148,18
16thweek of RT
Control 19,34 3,4 18,01 16,02 25,68
<0.001
IR 737,8 78,2 736,02 605,12 845,03
Hal (2.5)/C 21,33 4,66 20,33 15,66 29,02
Hal (5.0)/C 18,45 3,27 18,05 16,05 25,06
Hal (2.5)/IR 99,81 1,32 98,75 77,42 121,03
Hal (5.0)/IR 59,38 1,03 57,02 45,00 78,12
We found statistically significant differences in endocardial thickness between the study groups at 6 th weeks and 16th weeks of RT (p<0.001,
Kruskal-Wallis). The maximum endocardial thickening was observed in IR at 16th weeks of RT.
Electron microscopy
Thoracic aorta samples
There was a severe subendothelial edema in all the RT groups.
However there wasn’t any ultrastructural change in the tho-
racic aorta samples of the control group, Hal (2.5)/C and Hal
(5.0)/C groups. Subendothelial vacuoles were present in the
endothelial cells of H (2.5)/IR group. Additionally there was a
severe subendothelial edema in this group. The ultrastruc-
tural finding of Hal (5.0)/IR group was same with IR group.
When the subendothelial edema and the endothelial cell
scores were compared at 6th week of RT, there were signifi-
cant differences between all the groups (p values were <0.001
for both parameters). Pair-wise comparisons of RT groups
demonstrated that there were significant differences between
IR and Hal (2.5)/IR, IR and Hal (5.0)/IR regarding to suben-
dothelial edema scores; whereas there wasn’t any difference
between endothelial cell scores (p values were IR-Hal (2.5)/IR
<0.001 and 0.280 and IR-Hal (5.0)/IR 0.002 and 0.280 for
subendothelial edema and endothelial cell scores respective-
ly). On the other hand there wasn’t any difference in terms of
subendothelial edema and endothelial cell scores between
Hal (2.5)/IR and Hal (5.0)/IR (p values were 0.739 and >0.99
for subendothelial edema and endothelial cell scores respec-
tively)
Heart samples
There weren’t any ultrastructural changes in the heart sam-
ples of the Hal (2.5)/C and Hal (5.0)/C groups. The ultra-
structural findings of both Halofuginone groups were same
with control group. Histological examinations of the heart
sections revealed that separations in the myofibrils were
increased and the amount of glycogen was decreased in all of
the RT groups. Most of the mitochondria were swollen. The
perinuclear cisternae of the heart muscle cells were dilated
severely. The ultrastructural appearance of the intercalated
discs was damaged. In Hal (2.5)/IR group there were also
swollen mitochondria. The amount of the swollen mito-
chondria was the least in Hal (5.0)/IR group. In this group also
the ultrastructural appearance of the intercalated discs was
damaged.
TABLE 5: The mean of the cardiac mitochondria scores of the study
groups with electron microscopy.








Hal (2.5)/C 8.2±2.1 8.9±1.3
Hal (5.0)/C 8.2±1.6 9.1±2.3
Hal(2.5)/IR 117.7±3.9 112.5±5.8
Hal(5.0)/IR 110.5±2.7 93.2±3.9
Kruskal-Wallis test demonstrated that there was a significant
difference between all the groups with respect to heart mi-
tochondria scores at 6th week of RT (p < 0.001) (Table 5).
When all the RT groups compared in terms of the mito-
chondria scores at 6th week of RT the differences between
IR-Hal (2.5)/IR and IR- Hal (5.0)/IR were statistically signif-
icant (p values were <0.001 for each).
The pathological changes of the heart and the thoracic aorta




The histopathological findings of IR group were same with 6th
week findings. However there weren’t any changes in the
samples taken from the control group, Hal (2.5)/C and Hal
(5.0)/C; and Hal (2.5)/IR and Hal (5.0)/IR groups with H&E
staining.
Kruskal-Wallis test revealed that there were significant dif-
ferences within the study groups in terms of thoracic aorta
fibrosis scores (p = 0.002). There weren’t any changes in
non-RT groups. However; Mann-Whitney U test demon-
strated that there were significant differences between
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IR-Hal (2.5)/IR, IR-Hal (5.0)/IR (p = 0.007 and p = 0.002,
respectively).
Heart samples
H&E staining revealed extensive thickening in the endocar-
dium in IR group. On the other hand minimal endocardial
thickening was observed in Hal (2.5) IR and Hal (5.0)/IR
groups. Also, Tripple staining confirmed a severe subendo-
cardial fibrosis in IR group. However there were minimal
subendocardial fibrosis in the Hal (2.5) IR and Hal (5.0)/IR
groups (Figure 5).
There was a significant difference within the endocardial
thickness of all study groups at 16th week of RT (Table 4) (p <
0.001). The maximum thickness was observed in IR.
Pair-wise comparisons showed that there were significant
differences between IR and Hal (2.5)/IR (p < 0.001); IR and
Hal (5.0)/IR (p < 0.001) and; Hal (2.5)/IR and Hal (5.0)/IR (p =
0.001) regarding to endocardial thickness at 16th week of RT.
Electron microscopy
Thoracic aorta samples
There weren’t any ultrastructural changes in the thoracic
aorta samples of the control group, Hal (2.5)/C and Hal (5.0)/C
groups. On the other hand there were severe subendothelial
edema, separations and interruptions in the endothelium all
RT groups. The ultrastructural findings of all RT groups were
similar with respect to the thoracic aorta samples. When we
compared all the groups regarding to the subendothelial
edema and the endothelial cell scores at 16th week of RT,
there were significant differences between all the groups (p
values were <0.001 for both parameters).
At 16th week of RT, there were significant differences only in
between IR-Hal (2.5)/IR and IR-Hal (5.0)/IR in terms of en-
dothelial cell scores (p values were IR-Hal (2.5)/IR <0.001 and
IR-Hal (5.0)/IR = 0.003). On the other hand subendothelial
edema scores were not different for all the RT groups (p val-
ues were >0.99 for each).
Heart samples
There were no ultrastructural changes in the heart samples of
the control, Hal (2.5)/C and Hal (5.0)/C groups (Figure 1, 2).
The same ultrastructural findings were observed in IR group
when compared with 6th week’s findings. The perinuclear
cisternae of the heart muscle cells were dilated severely. The
ultrastructural appearance of the intercalated discs was
damaged. Amount of swollen mitochondria was increased.
Additionally fibrosis was observed in between the myofibrils
(Figure 3). Also the findings of Hal (2.5)/IR group were same
with 6th week findings. In Hal (5.0)/IR group the mitochon-
dria score was better than the previous heart samples (Figure
4). The separations in myofibrils were less than that of pre-
vious Hal (5.0)/IR group.
FIG. 1 (Heart sample of Control group at 16th week): Electron mi-
crograph showing normal cardiac structure (Original magnification
X7500).
FIG. 2 (Heart sample of Hal (5.0)/ C group at 16th week): Electron
micrograph showing ultrastructurally normal heart muscle (n =
nucleus of heart muscle cell; m = ultrastructurally normal mito-
chondria) (Original magnification X7500).
FIG. 3 (Heart sample of IR group at 16th week): Electron micrograph
showing separations in myofibrils (*), mitochondria with prominent
cristae (Mc) and fibrosis (f) (Original magnification X7500).
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FIG. 4 (Heart sample of Hal (5.0)/IR group at 16th week): Electron
micrograph showing mitochondria with prominent cristae (Mc).
Most of the mitochondria’s were swollen. The ultrastructural ap-
pearance of intercalated discs were damaged (N = nucleus; Mc =
mitochondrial cristae; M = mitochondria; d = discus intercalaris)
(Original magnification X7500).
FIG. 5a (Heart sample of Control group at 16th, Tripple staining):
Normal cardiac structure (X200)
FIG. 5b (Heart sample of IR group at 16th, Tripple staining): There
was extensive subendocardial fibrosis (X200)
FIG. 5c (Heart sample of Hal (2.5)/IR group at 16th week, Tripple
staining): There was minimal subendocardial fibrosis (X200).
FIG. 5d (Heart sample of Hal (5.0)/IR group at 16th week, Tripple
staining): There was minimal subendocardial fibrosis. (X200)
When the heart mitochondria scores were compared at 16th
week of RT, there were significant differences between all the
groups (p < 0.001) (Table 5). Mann-Whitney U test demon-
strated that there were significant differences between
IR-Hal (2.5)/IR, IR-Hal(5.0)/IR and Hal (2.5)/IR-Hal (5.0)/IR
in terms of mitochondria scores (p values were <0.001 for
IR-Hal (2.5)/IR and IR-Hal (5.0)/IR; and = 0.001 for Hal
(2.5)/IR-Hal (5.0)/IR).
Discussion
Although the heart was initially thought to be relatively
resistant to radiation-induced injury, cardiovascular dis-
eases resulting from therapeutic irradiation is now well
recognized.1-3 The worldwide number of long-term can-
cer survivors has been growing in parallel to the im-
provements in cancer therapies. However, long-term
survivors may suffer from late side effects of RT. One of
these side effects is radiation-induced cardiovascular
disease which may occur in patients who previously
treated with thoracic irradiation for Hodgkin’s disease
and breast cancer.
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Numerous studies of radiation-induced toxicity show that
“endothelial cell injury” is the key point in most tissues,
even though the endothelial cells compromise only a
minor fraction of cardiac cells.4, 10, 11 The sequence of
endothelial injury, cell detachment, thrombosis and fi-
brosis results in significant tissue injury that often limits
radiation oncologist in attempting to deliver curative
doses to a nearby tumor. The hallmark of radia-
tion-induced injury is extensive fibrosis. The fibrotic
phase tends to manifest >3 months RT. Fibrosis is a kind
of wound healing process. Transforming growth factor
β-1 (TGF-β1) plays an integral role in fibrosis formation




kaloid isolated from the Dichroa febrifuga plant, origi-
nally used in fowl as an anticoccidiostatic food supple-
ment, reduces avian skin collagen content. In vitro,
treating cultured dermal fibroblasts with Halofuginone
attenuates the incorporation of proline into collagenase
digestable proteins, without affecting the production of
non-collagenase digestible proteins, cell proliferation, or
collagen degradation. Halofuginone specifically inhibits
collagen α1 gene expression, resulted in a decrease in
collagen synthesis, and the TGF-β induced collagen syn-
thesis.8, 13, 14
It has been demonstrated that Halofuginone reduces
fibrosis formation in many pathological conditions.8, 13-19
Previously Halofuginone has shown to reduce fibrosis in
mice models with stretched skin due to scleroderma 20, to
decrease in the liver fibrosis model due to thiacetamide 21,
to lessen graft versus host disease 22, to improve muscular
dystrophies including dysferlinopathy 19, 23, and lessen
mesangial cell proliferation and matrix deposition in the
kidney.24 By the light of these studies, we hypothesized
that Halofuginone may be able to ameliorate radia-
tion-induced cardiovascular injury. Our results suggested
the Halofuginone improves radiation-induced cardio-
vascular injury. The most prominent improvement was
observed in higher dose of Halofuginone and after long
term follow-up in the heart samples.
Ertugrul and colleagues 25 administered intraperitoneal
Halofuginone for 30 days to a group of rats after they
traumatized the subglottic area, while they monitored the
second group as controls. In the histopathological exam-
inations of the subglottic areas, they found that fibrosis
formation was significantly less in rats treated with
Halofuginone when compared to that of control group.
Ozcelik and colleagues 26 administered intraperitoneal
Halofuginone for 21 days after producing corrosive sub-
stance injury in the rat esophagus using 50% NaOH. They
performed a histopathological examination and measured
the hydroxyproline levels of esophageal tissue of rats
killed on day 21 in order to assess the fibrosis and stenosis
index. Hydroxyproline levels and stricture formation in
the Halofuginone group were found to be signiﬁcantly
lower than that of the control group. Moreover Dabak
and colleagues 27 observed the effect of Halofuginone on
preventing esophageal and hypopharyngeal fibrosis and
suggested that Halofuginone can be used safely to prevent
radiation-induced esophageal and hypopharyngeal fibro-
sis.
Xavier and colleagues suggested new ideas on the molec-
ular mechanisms of the inhibition of TGF-β1 signal pro-
duction with Halofuginone, and demonstrated that
Halofuginone reduces the radiation-induced leg contrac-
tion in mice.8 Therefore the authors conducted a new
study to determine if less dosing of Halofuginone would
result in protection against leg contracture.17 In this study
authors used five daily doses of Halofuginone (instead of
seven) per week during 4 months of period. They
demonstrated that, Halofuginone is a protector against
radiation-induced leg contraction (fibrosis) by attenuat-
ing the induction of key members of the TGF- β signaling
pathway. The authors also showed that Halofuginone did
not protect against radiation-induced tumor re-growth
delay. Therefore the authors conducted a new study to
determine if Halofuginone might enhance the radiosen-
sitivity of human tumor cell lines.28 Their study revealed
that Halofuginone treatment inhibited cell growth, halted
cell cycle progression, decreased radiation-induced DNA
damage repair and decreased TGF-β receptor II protein
levels, leading to increased cellular radiosensitization.
In the current study we compared two different doses of
Halofuginone. Different from the study by Ishii and col-
leagues, we applied the Halofuginone during whole week
including the weekends. Our results suggested that using
5 μg Halofuginone resulted in more prominent im-
provement. This finding was observed at 6th week of RT as
well as 16th week of RT. When we compared the 2.5 μg
Halofuginone+RT and 5 μg Halofuginone+RT groups at
16th week of RT, we found a significant difference be-
tween two groups with respect to endocardial thickness
scores. On the other hand at 6th week of RT we could not
demonstrate any significant differences between thoracic
aorta samples of the RT groups. However, at 16th week of
RT electron microscopy revealed that endothelial damage
was more prominent in RT only group when compared to
that of RT+Halofuginone groups. In the same manner
light microscopy revealed that at 16th week of RT there
were severe fibrosis in the thoracic aorta samples of RT
only group however this finding was not observed in
RT+Halofuginone groups.
In a current study investigating the effects of concomitant
RT and Trastuzumab on vascular structures two different
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doses of RT were compared: 8 Gy and 15 Gy.9 The 8 Gy
dose of RT was not enough to cause significant changes
both from functional and morphological aspects. On the
other hand 15 Gy RT led significant changes. In the cur-
rent study we used a RT dose between these two doses.
Our results suggested that 12 Gy RT seems to be enough
in order to observe radiation-induced cardiovascular
toxicity in rat studies.
Conclusion
The current study is the first one observing the effect of
Halofuginone on radiation-induced cardiovascular injury.
Our results suggested that the use of Halofuginone im-
proves radiation-induced injury on the heart as well as
the thoracic aorta. The effect was more prominent in the
heart samples when compared to the thoracic aorta sam-
ples, at higher dose and after long term follow-up. This
finding should be clarified with further clinical studies.
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